M Weda

444 total citations
27 papers, 205 citations indexed

About

M Weda is a scholar working on Pulmonary and Respiratory Medicine, Pediatrics, Perinatology and Child Health and Economics and Econometrics. According to data from OpenAlex, M Weda has authored 27 papers receiving a total of 205 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Pediatrics, Perinatology and Child Health and 5 papers in Economics and Econometrics. Recurrent topics in M Weda's work include Inhalation and Respiratory Drug Delivery (7 papers), Pharmaceutical studies and practices (6 papers) and Healthcare Policy and Management (3 papers). M Weda is often cited by papers focused on Inhalation and Respiratory Drug Delivery (7 papers), Pharmaceutical studies and practices (6 papers) and Healthcare Policy and Management (3 papers). M Weda collaborates with scholars based in Netherlands, Denmark and United States. M Weda's co-authors include D.M. Barends, Pieter Zanen, Henderik W. Frijlink, Anne H. de Boer, Marlies Kubbinga, Martijn Bouwknegt, Wilfrid van Pelt, Arie H. Havelaar, D. de Kaste and Doetie Gjaltema and has published in prestigious journals such as The Lancet, International Journal of Pharmaceutics and European Journal of Pharmaceutics and Biopharmaceutics.

In The Last Decade

M Weda

23 papers receiving 196 citations

Peers

Countries citing papers authored by M Weda

Since Specialization

Citations

This map shows the geographic impact of M Weda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Weda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Weda more than expected).

Fields of papers citing papers by M Weda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Weda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Weda. The network helps show where M Weda may publish in the future.

Co-authorship network of co-authors of M Weda

This figure shows the co-authorship network connecting the top 25 collaborators of M Weda. A scholar is included among the top collaborators of M Weda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Weda. M Weda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Exposure to and toxicity of methyl-, ethyl- and propylparaben : A literature review with a focus on endocrine-disrupting properties 2018 ·Rivm (National Institute for Public Health and the Environment) ·Walter Brand, (unknown), (unknown), (unknown), M Weda, (unknown)	5
2	Horizon scan of medical technologies 2018 ·Rivm (National Institute for Public Health and the Environment) ·(unknown), (unknown), (unknown), M Weda, MA Koopmanschap, (unknown)	1
3	Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity 2017 ·Frontiers in Pharmacology ·Marleen E. Jansen, Tessel Rigter, Wendy Rodenburg, (unknown), Elisa J. F. Houwink, M Weda, Martina C. Cornel	16
4	Characterization of Apps and Other e-Tools for Medication Use: Insights Into Possible Benefits and Risks 2016 ·JMIR mhealth and uhealth ·Linda W. M. van Kerkhof, (unknown), (unknown), M Weda, (unknown)	16
5	Patiëntenperspectief op veilige zorg rondom medicijnen 2016 ·Rivm (National Institute for Public Health and the Environment) ·(unknown), M Weda	0
6	[Pharmacogenetics in primary health care: implementation and future expectations]. 2015 ·PubMed ·Elisa J. F. Houwink, Tessel Rigter, Jesse J. Swen, Martina C. Cornel, Anne S. Kienhuis, Wendy Rodenburg, M Weda	3
7	Farmacogenetica in de eerstelijnszorg. Toepassingen en toekomstverwachtingen 2015 ·Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank ·(unknown), (unknown), Jesse J. Swen, Martina C. Cornel, (unknown), (unknown), M Weda	0
8	Polyfarmacie bij kwetsbare ouderen : Risico's rondom overgangen tussen eerste en tweedelijnszorg 2015 ·Rivm (National Institute for Public Health and the Environment) ·(unknown), M Weda	2
9	Potential association between the recent increase in campylobacteriosis incidence in the Netherlands and proton-pump inhibitor use – an ecological study 2014 ·Eurosurveillance ·Martijn Bouwknegt, Wilfrid van Pelt, Marlies Kubbinga, M Weda, Arie H. Havelaar	32
10	Personalised medicine products : evaluation of the regulatory framework 2014 ·Rivm (National Institute for Public Health and the Environment) ·M Weda, (unknown), (unknown), (unknown), (unknown), (unknown), Stein J. Janssen	1
11	Recent increase in campylobacteriosis incidence in the Netherlands associated with proton-pump inhibitor use 2013 ·The Lancet ·Martijn Bouwknegt, Wilfrid van Pelt, Marlies Kubbinga, M Weda, Arie H. Havelaar	1
12	On the formation of bromhexine impurity E and its chromatographic behaviour. 2012 ·PubMed ·(unknown), M Weda, (unknown), (unknown)	1
13	Consistency of FMEA used in the validation of analytical procedures 2010 ·Journal of Pharmaceutical and Biomedical Analysis ·(unknown), (unknown), Maarten Nauta, D. de Kaste, (unknown), M.J. Vredenbregt, M Weda, D.M. Barends	33
14	Storage Instructions for Inhalation Capsules 2010 ·Journal of Pharmacy Practice ·(unknown), (unknown), Matthijs J. van Haren, Marcel L. Bouvy, M Weda	9
15	The Therapeutic Index of Locally Acting Inhaled Drugs as a Function of their Fine Particle Mass and Particle Size Distribution – A Literature Review 2008 ·Current Drug Delivery ·M Weda, Pieter Zanen, (unknown), D.M. Barends, Henderik W. Frijlink	7
16	An investigation into the predictive value of cascade impactor results for side effects of inhaled salbutamol 2004 ·International Journal of Pharmaceutics ·M Weda, Pieter Zanen, Anne H. de Boer, D.M. Barends, Henderik W. Frijlink	27
17	Drug output of unvented jet nebulizers as a function of time 2003 ·International Journal of Pharmaceutics ·(unknown), P.P.H. Le Brun, Henderik W. Frijlink, Paul Vitányi, M Weda, D.M. Barends	3
18	Equivalence testing of salbutamol dry powder inhalers: in vitro impaction results versus in vivo efficacy 2002 ·International Journal of Pharmaceutics ·M Weda, Pieter Zanen, Anne H. de Boer, Doetie Gjaltema, (unknown), D.M. Barends, Henderik W. Frijlink	26
19	Metal versus plastic spacers: an in vitro and in vivo comparison 2002 ·International Journal of Pharmaceutics ·Rob Janssen, M Weda, Miquel B. Ekkelenkamp, (unknown), Pieter Zanen	3
20	Equivalence testing and equivalence limits of metered-dose inhalers and dry powder inhalers measured by in vitro impaction 2000 ·European Journal of Pharmaceutics and Biopharmaceutics ·M Weda, (unknown), (unknown), (unknown), (unknown), A. Bult, Pieter Zanen, D.M. Barends	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact